Hyperthyroidism: Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
114 |
4. Check minimum number of eventsNone |
114 |
5. Include endpointsNone |
114 |
6. Filter based on genotype QC (FinnGen only) |
113 |
Control definitions (FinnGen only)
- Control exclude
- THYROTOXICOSIS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E05
- Name in latin
- Thyreotoxicosis factitia
Similar endpoints
↥List of similar endpoints to
Thyrotoxicosis factitia
based on the number of shared cases.
Similar with more cases:
- Thyrotoxicosis, other and/or unspecified
- Thyrotoxicosis
- Disorders of thyroid, IBD co-morbidities
- Developmental endpoint to exclude non autoimmune-cases from E4_HYTHY_AI_STRICT
- Disorders of the thyroid gland
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 609 | 533 | 72 |
| Only index persons | 568 | 503 | 65 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.00 |
| Only index persons | 0.02 | 0.02 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 61.75 | 61.52 | 63.95 |
| Only index persons | 60.75 | 60.51 | 62.60 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 113 | 105 | 8 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.00 |
| Median age at first event (years) | 57.33 | 56.09 | 73.52 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 114
- Matched controls
- 1140
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E05.4
ICD-10 Finland
Thyrotoxicosis factitia
+∞
158.7
112
*
H03AA01
ATC
levothyroxine sodium; systemic
71.5
62.5
107
200
104
Kela drug reimbursment
Thyroid insufficiency
18.8
53.4
54
52
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
14.1
47.2
69
112
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
384.3
30.3
29
*
H03BB01
ATC
carbimazole; oral
192.2
29.1
29
*
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
+∞
19.3
18
*
E03.89
ICD-10 Finland
Other specified hypothyroidism
16.5
16.2
26
20
E03
ICD-10 Finland
Other hypothyroidism
6.7
15.1
28
53
C07AA05
ATC
propranolol; systemic
3.5
9.2
46
186
BAA60
NOMESCO Finland
Total thyroidectomy
15.7
9.0
14
10
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
13.1
7.8
13
11
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
+∞
7.4
7
*
E89.00
ICD-10 Finland
Postirradiation hypothyroidism
+∞
7.4
7
*
E05
ICD-10 Finland
Thyrotoxicosis [hyperthyroidism]
+∞
7.4
7
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.3
7.0
33
126
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
7.0
23
69
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
18.1
6.9
10
6
M01AH01
ATC
celecoxib; oral
3.1
6.6
34
136
E05.80
ICD-10 Finland
Subacute thyrotoxicosis
+∞
6.3
6
*
H02AB09
ATC
hydrocortisone; systemic
9.4
6.2
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
49
25.63
68.12
6.9
1.9
4.44
4.43
pmol/l
0.03
53
41
39
96
5.66
16.03
2.2
2.1
337.85
384.96
nmol/l
0.78
33
90
32
78
5.31
13.08
1.2
1.3
282.44
156.71
iu/ml
0.51
13
31
67
337
3.40
9.41
2.7
2.8
2.34
2.37
mmol/l
0.31
61
302
46
196
3.26
8.31
1.9
1.7
460.28
492.70
pmol/l
0.34
36
162
79
465
3.28
8.07
7.7
5.8
1.22
1.22
mmol/l
0.37
61
393
73
411
3.16
8.05
16.6
10.7
1.17
1.18
inr
0.04
24
128
69
378
3.09
7.96
2.2
1.9
96.64
95.71
pmol/l
0.04
38
169
57
306
2.73
6.45
2.7
2.1
150.56
137.02
u/l
0.14
52
290
44
216
2.69
5.83
2.6
2.0
2.93
3.13
mg/l
0.24
32
181
51
270
2.61
5.80
3.5
3.3
782.83
1008.10
ng/l
0.28
40
223
36
161
2.81
5.69
1.8
1.7
1251.51
1195.58
nmol/l
0.16
28
116
61
357
2.52
5.56
5.6
3.8
17.50
32.84
ng/l
0.72
42
238
72
460
2.53
5.37
3.6
2.6
79.97
74.76
ug/l
0.24
66
419
79
530
2.60
5.26
5.5
4.5
6.83
6.51
mmol/l
0.48
74
484
70
449
2.45
5.07
2.8
2.2
81.59
76.58
nmol/l
0.67
61
396
99
752
3.41
5.06
5.3
4.0
11.88
11.54
mm/h
0.09
93
688
54
309
2.42
5.05
2.6
3.0
29.33
29.15
u/l
0.02
48
295
44
235
2.42
4.74
1.5
1.4
16.54
22.62
nmol/l
2.76
38
195
28
121
2.74
4.64
1.8
1.8
28.47
29.44
s
0.44
28
116
81
570
2.45
4.56
6.5
8.9
3.58
4.00
e9/l
1.01
73
506
44
240
2.36
4.48
1.6
1.3
0.56
1.18
u/ml
1.03
13
61
11
20
5.96
4.41
8.5
3.5
7.38
7.08
mmol/l
0.18
11
20
61
385
2.26
4.37
5.5
3.8
—
—
—
0
0
11
21
5.68
4.26
8.5
3.4
1.27
1.44
mmol/l
0.53
11
21
64
425
2.15
3.90
6.5
5.4
1.21
1.22
mmol/l
0.65
57
381
105
889
3.29
3.82
8.3
5.3
40.11
39.16
mmol/mol
0.38
94
817
9
16
6.01
3.74
4.4
2.9
106.11
108.19
mmol/l
—
9
16
16
58
3.05
3.59
1.8
1.5
—
—
—
0
0
13
44
3.21
3.25
4.5
2.5
0.84
1.10
%
0.51
13
44
107
935
3.35
3.23
5.9
4.4
5.96
5.77
mmol/l
0.62
97
854
109
967
3.90
3.18
19.9
13.2
13.67
21.69
mg/l
3.40
93
730
69
495
2.00
3.17
7.6
5.1
0.00
0.00
estimate
-0.00
20
92
69
499
1.97
3.06
5.3
3.8
0.00
0.00
estimate
-0.00
19
92
38
224
2.04
3.02
1.6
1.8
0.52
1.14
mg/l
2.78
31
182
5
5
10.37
3.00
2.0
1.2
6.28
10.20
umol/l
—
5
5
68
498
1.91
2.81
5.4
3.7
0.00
0.00
estimate
-0.00
22
97
12
41
3.15
2.72
4.5
2.5
0.74
0.67
%
0.38
12
41
83
654
1.99
2.70
3.8
2.8
41.41
41.73
u/l
0.02
78
610
40
252
1.90
2.58
4.3
3.5
4.51
7.20
mg/mmol
0.31
20
154
109
986
3.40
2.53
26.0
14.6
139.29
139.77
mmol/l
0.87
109
951
7
17
4.31
2.40
1.1
1.2
—
—
—
0
0
13
53
2.64
2.37
1.1
1.0
—
—
—
0
0
109
987
3.38
2.36
25.6
14.7
3.93
3.93
mmol/l
0.08
109
949
12
48
2.68
2.27
1.8
4.0
0.01
0.14
e6/l
1.30
12
48
33
203
1.88
2.26
1.7
1.6
—
—
—
0
0
15
68
2.39
2.22
1.3
1.4
—
—
—
0
0
24
139
1.92
1.95
1.5
1.8
—
—
—
0
0
14
66
2.28
1.91
8.5
2.8
4.90
4.16
kpa
1.33
14
66
39
266
1.71
1.87
5.2
4.1
0.00
0.00
estimate
-0.00
18
93
11
47
2.48
1.84
1.1
1.7
—
—
—
0
0
105
953
2.29
1.83
5.3
4.3
4.70
4.74
mmol/l
0.17
92
874
17
89
2.07
1.81
4.9
3.8
—
—
—
0
0
45
322
1.66
1.79
3.7
3.1
—
—
—
0
0
39
269
1.68
1.78
3.6
2.8
0.14
0.53
e6/l
1.82
33
199
11
48
2.43
1.76
4.4
5.4
26.12
25.56
mmol/l
0.22
11
48
102
910
2.15
1.74
18.4
12.9
81.36
82.03
ml/min/173m2
0.10
84
717
5
13
3.97
1.73
1.4
1.2
—
—
—
0
0
9
40
2.35
1.44
1.3
1.4
—
—
—
0
0
18
105
1.85
1.43
5.9
6.1
106.11
103.82
mmol/l
1.42
18
105
105
970
2.04
1.32
5.9
4.8
2.74
2.76
mmol/l
0.09
93
883
5
18
2.86
1.30
1.2
1.4
—
—
—
0
0
6
25
2.48
1.26
1.5
1.1
—
—
—
0
0
28
193
1.60
1.25
1.2
1.3
2.09
8.83
u/ml
1.19
13
80
8
37
2.25
1.24
1.1
1.8
—
—
—
0
0
28
194
1.59
1.22
1.3
1.3
22.20
36.65
iu/ml
—
5
67
8
38
2.19
1.21
1.1
1.8
—
—
—
0
0
6
26
2.38
1.20
1.5
1.3
—
—
—
0
0
5
20
2.57
1.16
1.8
1.5
—
—
—
0
0
95
860
1.63
1.12
24.9
15.8
13.57
14.91
%
6.68
95
849
15
91
1.75
1.07
1.5
1.8
—
—
—
0
0
102
946
1.74
1.01
5.6
4.2
1.49
1.58
mmol/l
1.12
91
860
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
9
51
1.83
0.97
1.6
1.3
—
—
—
0
0
7
37
1.95
0.96
1.3
1.2
—
—
—
0
0
7
37
1.95
0.96
1.3
1.2
—
—
—
0
0
14
88
1.67
0.89
1.4
1.8
—
—
—
0
0
30
229
1.42
0.83
2.1
2.4
329.86
5955.55
umol/l
1.30
21
197
97
904
1.49
0.75
5.1
3.8
1.40
1.19
mmol/l
1.47
88
816
21
154
1.45
0.71
2.5
2.4
0.73
0.82
e6/l
0.13
15
89
5
95
0.50
0.70
2.4
1.7
—
—
—
0
0
5
29
1.76
0.64
1.6
1.4
199.62
141.85
ug/l
—
5
24
0
21
0.00
0.60
0.0
1.6
—
—
—
0
0
6
38
1.61
0.55
2.0
1.6
—
—
—
0
0
6
39
1.57
0.54
1.5
1.3
—
—
—
0
0
19
145
1.37
0.53
2.6
2.7
7.00
4.10
e6/l
0.50
13
81
15
112
1.39
0.47
9.9
6.9
—
—
—
0
0
11
77
1.47
0.47
1.9
2.5
0.24
0.21
g/l
0.50
11
72
50
442
1.23
0.47
2.8
2.4
—
—
—
0
0
22
176
1.31
0.46
7.2
3.5
36.33
164.84
ng/l
0.99
15
131
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
5
34
1.49
0.41
1.4
2.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
8
65
1.25
0.28
2.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
72.20
—
0
5
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
22
238
0.91
0.11
1.4
1.4
—
—
—
0
0
10
88
1.15
0.08
2.2
1.6
—
—
—
0
0
13
137
0.94
0.01
3.2
2.1
—
—
—
0
0
63
637
0.98
0.01
2.8
3.2
—
—
—
0
0
21
216
0.97
0.00
2.1
2.0
—
—
—
0
0
12
123
0.97
0.00
3.1
1.9
—
—
—
0
0
28
276
1.02
0.00
1.5
1.6
1.47
1.30
mmol/l
0.40
17
229
0
5
0.00
0.00
0.0
1.2
—
0.30
—
0
5
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
10.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
11.00
—
0
5
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
118.12
—
0
5
0
5
0.00
0.00
0.0
1.0
—
9.29
—
0
5
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
117.20
—
0
5
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
57.50
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
22.00
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
37.35
—
0
6
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_THYTOXFAC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_THYTOXFAC | 1.608 [1.15, 2.24] | 0.005 |
| Birth year | 0.997 [0.99, 1.01] | 0.534 |
During the follow-up period (1.1.1998 — 31.12.2019), 95 out of 465 females with E4_THYTOXFAC died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have E4_THYTOXFAC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.149% | No data |
| 5 | 1.053% | No data |
| 10 | 2.484% | No data |
| 15 | 4.999% | No data |
| 20 | 8.612% | No data |
Relationships between endpoints
↥Index endpoint: E4_THYTOXFAC – Thyrotoxicosis factitia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data